financetom
Business
financetom
/
Business
/
Regenxbio Closes Partnership With Nippon Shinyaku
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Regenxbio Closes Partnership With Nippon Shinyaku
Mar 4, 2025 5:56 AM

08:35 AM EST, 03/04/2025 (MT Newswires) -- Regenxbio ( RGNX ) said Tuesday that it has closed its partnership with Japanese pharmaceutical and health food company Nippon Shinyaku.

The clinical-stage company said the agreement requires it and Nippon Shinyaku to develop and commercialize RGX-121 to treat patients with Hunter syndrome, and RGX-111 to treat Hurler syndrome in the US and Asia.

Regenxbio ( RGNX ) said RGX-121 is set to be the first gene therapy for Hunter syndrome, with FDA approval expected as early as late this year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved